Home
NBIX
NBIX News

Latest Neurocrine Biosciences Inc. (NBIX) News on April 9, 2025

Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options

Zacks

2 days ago

Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options

MT Newswires

5 days ago

Neurocrine Biosciences Appoints New Chief Medical Officer

Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer

PR Newswire

5 days ago

Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer

MT Newswires

5 days ago

UBS Lowers Price Target on Neurocrine Biosciences to $137 From $154, Keeps Buy Rating

MT Newswires

5 days ago

Deutsche Bank Adjusts Neurocrine Biosciences Price Target to $135 From $138, Maintains Hold Rating

MT Newswires

6 days ago

RBC Trims Price Target on Neurocrine Biosciences to $138 From $139, Keeps Sector Perform Rating

Argus Research

7 days ago

NBIX: Lowering target price to $112.00

Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia

PR Newswire

9 days ago

Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia

Argus Research

14 days ago

NBIX: Raising target price to $122.00

Exploring High Growth Tech Stocks in US for March 2025

Simply Wall St.

15 days ago

Exploring High Growth Tech Stocks in US for March 2025

Neurocrine Biosciences debuts new data for effectiveness of Ingrezza

Clinical Trials Arena

20 days ago

Neurocrine Biosciences debuts new data for effectiveness of Ingrezza

Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules

PR Newswire

20 days ago

Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules

Neurocrine Biosciences (NBIX): Among the Best Biotech Stocks to Buy According to Billionaires

Insider Monkey

22 days ago

Neurocrine Biosciences (NBIX): Among the Best Biotech Stocks to Buy According to Billionaires

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules

PR Newswire

23 days ago

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.

The Wall Street Journal

a month ago

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.

Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum

PR Newswire

a month ago

Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum

MT Newswires

a month ago

RBC Cuts Price Target on Neurocrine Biosciences to $139 From $148, Keeps Sector Perform Rating

Neurocrine Biosciences (NasdaqGS:NBIX) Begins Phase 1 Study Of New VMAT2 Inhibitor For Neurological Conditions

Simply Wall St.

a month ago

Neurocrine Biosciences (NasdaqGS:NBIX) Begins Phase 1 Study Of New VMAT2 Inhibitor For Neurological Conditions

Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adults

Clinical Trials Arena

a month ago

Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adults

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

PR Newswire

a month ago

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

Argus Research

a month ago

NBIX: Lowering target price to $119.00

Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures

PR Newswire

a month ago

Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures

Argus Research

a month ago

NBIX: Raising target price to $122.00

Neurocrine Biosciences to Present at Upcoming Investor Conferences in March

PR Newswire

a month ago

Neurocrine Biosciences to Present at Upcoming Investor Conferences in March

High Growth Tech Stocks To Watch In February 2025

Simply Wall St.

a month ago

High Growth Tech Stocks To Watch In February 2025

Is Neurocrine Biosciences (NBIX) One of the Best Fast Growth Stock to Buy Right Now?

Insider Monkey

2 months ago

Is Neurocrine Biosciences (NBIX) One of the Best Fast Growth Stock to Buy Right Now?

Neurocrine Biosciences' (NASDAQ:NBIX) Performance Is Even Better Than Its Earnings Suggest

Simply Wall St.

2 months ago

Neurocrine Biosciences' (NASDAQ:NBIX) Performance Is Even Better Than Its Earnings Suggest

MT Newswires

2 months ago

Sector Update: Health Care Stocks Mixed Premarket Friday

MT Newswires

2 months ago

Neurocrine Biosciences Approves $500 Million Share Repurchase Program

Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program

PR Newswire

2 months ago

Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program

Argus Research

2 months ago

NBIX: Lowering target price to $120.00

Neurocrine (NBIX): Among Top Insider Stock Buys And Sells In January

Insider Monkey

2 months ago

Neurocrine (NBIX): Among Top Insider Stock Buys And Sells In January

MT Newswires

2 months ago

Neurocrine Biosciences Insider Sold Shares Worth $1,613,923, According to a Recent SEC Filing

MT Newswires

2 months ago

Deutsche Bank Initiates Coverage on Neurocrine Biosciences With Hold Rating, $138 Price Target

Why Neurocrine Biosciences Stock Sank Today

Motley Fool

2 months ago

Why Neurocrine Biosciences Stock Sank Today

MT Newswires

2 months ago

UBS Adjusts Neurocrine Biosciences Price Target to $154 From $176, Maintains Buy Rating

Why Neurocrine Biosciences Inc. (NBIX) Crashed Last Week

Insider Monkey

2 months ago

Why Neurocrine Biosciences Inc. (NBIX) Crashed Last Week

Here’s Why Neurocrine Biosciences Inc. (NBIX) Crashed on Friday

Insider Monkey

2 months ago

Here’s Why Neurocrine Biosciences Inc. (NBIX) Crashed on Friday

Neurocrine Biosciences' (NASDAQ:NBIX) underlying earnings growth outpaced the notable return generated for shareholders over the past three years

Simply Wall St.

2 months ago

Neurocrine Biosciences' (NASDAQ:NBIX) underlying earnings growth outpaced the notable return generated for shareholders over the past three years

Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug

Investor's Business Daily

2 months ago

Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug

These Stocks Moved the Most Today: Amazon, Tesla, Uber, Affirm, Pinterest, Take-Two, Expedia, Bill, e.l.f. Beauty, and More

Barrons.com

2 months ago

These Stocks Moved the Most Today: Amazon, Tesla, Uber, Affirm, Pinterest, Take-Two, Expedia, Bill, e.l.f. Beauty, and More

Why Is Neurocrine Biosciences Stock Trading Lower On Friday?

Benzinga

2 months ago

Why Is Neurocrine Biosciences Stock Trading Lower On Friday?

MT Newswires

2 months ago

RBC Capital Adjusts Price Target on Neurocrine Biosciences to $148 From $154, Keeps Sector Perform Rating

MT Newswires

2 months ago

Wedbush Adjusts Price Target on Neurocrine Biosciences to $147 From $157, Keeps Outperform Rating

MT Newswires

2 months ago

Sector Update: Health Care Stocks Lower Pre-Bell Friday

These Stocks Are Moving the Most Today: Amazon, Tesla, Affirm, Pinterest, Take-Two, Expedia, Bill, e.l.f. Beauty, and More

Barrons.com

2 months ago

These Stocks Are Moving the Most Today: Amazon, Tesla, Affirm, Pinterest, Take-Two, Expedia, Bill, e.l.f. Beauty, and More

MT Newswires

2 months ago

Sector Update: Health Care

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Neurocrine Biosciences Inc Earnings Call

GuruFocus.com

2 months ago

Neurocrine Biosciences Inc (NBIX) Q4 2024 Earnings Call Highlights: Record INGREZZA Growth and ...

Neurocrine Biosciences (NBIX) Q4 Earnings and Revenues Lag Estimates

Zacks

2 months ago

Neurocrine Biosciences (NBIX) Q4 Earnings and Revenues Lag Estimates

Argus Research

2 months ago

NBIX: Raising target price to $160.00

MT Newswires

2 months ago

Neurocrine Biosciences Insider Sold Shares Worth $413,967, According to a Recent SEC Filing

Neurocrine Biosciences, Inc. (NBIX): Among the Best Low Risk High Growth Stocks To Invest In Now

Insider Monkey

2 months ago

Neurocrine Biosciences, Inc. (NBIX): Among the Best Low Risk High Growth Stocks To Invest In Now

Neurocrine (NBIX) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Zacks

2 months ago

Neurocrine (NBIX) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results

PR Newswire

2 months ago

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results

MT Newswires

2 months ago

Neurocrine Biosciences Insider Sold Shares Worth $21,836,503, According to a Recent SEC Filing

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Q4 Release

Zacks

2 months ago

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Q4 Release

Argus Research

2 months ago

NBIX: Raising target price to $158.00

MT Newswires

2 months ago

Neurocrine Biosciences Begins Phase 3 Study of Osavampator in Major Depressive Disorder

Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights

Benzinga

2 months ago

Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights

Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults

PR Newswire

2 months ago

Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults

MT Newswires

2 months ago

Neurocrine Amends Collaboration with Takeda on Osavampator

Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)

PR Newswire

2 months ago

Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)

Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device

PR Newswire

3 months ago

Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device

MT Newswires

3 months ago

Wedbush Lifts Price Target on Neurocrine Biosciences to $157 From $154, Keeps Outperform Rating

Argus Research

3 months ago

NBIX: Rating increased to a HOLD

Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism

PR Newswire

3 months ago

Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism

MT Newswires

3 months ago

Neurocrine Biosciences Insider Sold Shares Worth $9,197,550, According to a Recent SEC Filing

Argus Research

3 months ago

NBIX: Raising target price to $112.00

Exploring High Growth Tech Stocks in January 2025

Simply Wall St.

3 months ago

Exploring High Growth Tech Stocks in January 2025

MT Newswires

3 months ago

UBS Raises Price Target on Neurocrine Biosciences to $162 From $142, Keeps Buy Rating

Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism

PR Newswire

3 months ago

Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism

MT Newswires

3 months ago

RBC Boosts Price Target on Neurocrine Biosciences to $159 From $136, Keeps Sector Perform Rating

Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

PR Newswire

3 months ago

Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Neurocrine Biosciences Stock Sees RS Rating Upgrade

Investor's Business Daily

4 months ago

Neurocrine Biosciences Stock Sees RS Rating Upgrade

Argus Research

4 months ago

NBIX: What does Argus have to say about NBIX?

Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last?

Zacks

4 months ago

Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last?

MT Newswires

4 months ago

Wedbush Raises Price Target on Neurocrine Biosciences to $154 From $148, Keeps Outperform Rating

MT Newswires

4 months ago

Neurocrine Biosciences Starts Commercial Sales of New Congenital Adrenal Hyperplasia Treatment

Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia

PR Newswire

4 months ago

Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia

Argus Research

4 months ago

NBIX: Raising target price to $144.00

Neurocrine Jumps After Snagging FDA Approval For A First-In-Decades Drug

Investor's Business Daily

4 months ago

Neurocrine Jumps After Snagging FDA Approval For A First-In-Decades Drug

Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential

Benzinga

4 months ago

Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential

MT Newswires

4 months ago

Neurocrine Biosciences' Crenessity Approved by FDA for Classic Congenital Adrenal Hyperplasia

Neurocrine Wins FDA Approval For Genetic Disorder Drug

Investor's Business Daily

4 months ago

Neurocrine Wins FDA Approval For Genetic Disorder Drug

Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia

PR Newswire

4 months ago

Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia

Exploring Three High Growth Tech Stocks In The United States

Simply Wall St.

4 months ago

Exploring Three High Growth Tech Stocks In The United States

Argus Research

4 months ago

NBIX: Raising target price to $135.00

Argus Research

4 months ago

NBIX: Lowering target price to $132.00

Why Is Neurocrine Biosciences, Inc. (NBIX) Among the Best High Growth Healthcare Stocks to Invest In Now?

Insider Monkey

4 months ago

Why Is Neurocrine Biosciences, Inc. (NBIX) Among the Best High Growth Healthcare Stocks to Invest In Now?

Why Neurocrine Biosciences (NBIX) Is the Most Profitable Pharmaceutical Stock Right Now?

Insider Monkey

4 months ago

Why Neurocrine Biosciences (NBIX) Is the Most Profitable Pharmaceutical Stock Right Now?

Neurocrine Biosciences to Participate at Investor Conferences in December

PR Newswire

4 months ago

Neurocrine Biosciences to Participate at Investor Conferences in December

Argus Research

5 months ago

NBIX: Raising target price to $133.00

High Growth Tech Stocks Featuring Three Prominent US Companies

Simply Wall St.

5 months ago

High Growth Tech Stocks Featuring Three Prominent US Companies

Neurocrine Biosciences' (NASDAQ:NBIX) Strong Earnings Are Of Good Quality

Simply Wall St.

5 months ago

Neurocrine Biosciences' (NASDAQ:NBIX) Strong Earnings Are Of Good Quality

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules

PR Newswire

5 months ago

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules

Argus Research

5 months ago

NBIX: Raising target price to $128.00

Neurocrine Biosciences to Participate at Investor Conferences in November

PR Newswire

5 months ago

Neurocrine Biosciences to Participate at Investor Conferences in November

Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules

PR Newswire

5 months ago

Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules

Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia

PR Newswire

5 months ago

Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia

Share on Social Networks: